Document Detail


Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
MedLine Citation:
PMID:  17627710     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: This was a post hoc analysis to determine whether baseline severity of depression influenced the efficacy of duloxetine in treating major depressive disorder (MDD) and to better characterise the symptom response profile for duloxetine in patients with mild, moderate or more severe depression. METHODS: Data were pooled from four double-blind, placebo-controlled studies in which outpatients with MDD were randomised to duloxetine (60 mg/day) or placebo for 8-9 weeks. Patients were retrospectively stratified according to baseline 17-item Hamilton Depression Rating scale (HAMD17) total scores: mild=total score<or=19 (duloxetine, n=246; placebo, n=184); moderate=20-24 (duloxetine, n=333; placebo, n=217); severe=25+ (duloxetine, n=127; placebo, n=87). RESULTS: Duloxetine produced significantly greater baseline-to-end-point improvement vs. placebo (p<0.05) on the HAMD17 total score, Maier and retardation subscales, HAMD17 items 1 (depressed mood), 7 (work and activities) and 10 (psychic anxiety) in all three patient cohorts. The largest effect sizes were observed in assessments of core emotional depressive symptoms. A significant improvement for duloxetine vs. placebo was not observed for sleep-related symptoms at end-point or genital symptoms at any time point during acute treatment. With respect to the time course of depressive symptom improvement, the data show that regardless of baseline severity, the most rapid and consistent improvement for duloxetine compared with placebo was observed in the core symptoms of MDD (measured by the Maier subscale). CONCLUSION: Regardless of baseline MDD severity, duloxetine at one dose (60 mg/day) produced a significant improvement compared with placebo on the core emotional symptoms of MDD.
Authors:
R C Shelton; A Prakash; C H Mallinckrodt; M M Wohlreich; J Raskin; M J Robinson; M J Detke
Publication Detail:
Type:  Journal Article; Meta-Analysis; Review    
Journal Detail:
Title:  International journal of clinical practice     Volume:  61     ISSN:  1368-5031     ISO Abbreviation:  Int. J. Clin. Pract.     Publication Date:  2007 Aug 
Date Detail:
Created Date:  2007-07-13     Completed Date:  2007-12-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9712381     Medline TA:  Int J Clin Pract     Country:  England    
Other Details:
Languages:  eng     Pagination:  1337-48     Citation Subset:  IM    
Affiliation:
Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, and McLean Hospital, Belmont, MA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antidepressive Agents / therapeutic use*
Cohort Studies
Depressive Disorder, Major / drug therapy*
Double-Blind Method
Female
Humans
Male
Middle Aged
Multicenter Studies as Topic
Psychiatric Status Rating Scales
Randomized Controlled Trials as Topic
Severity of Illness Index
Thiophenes / therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antidepressive Agents; 0/Thiophenes; 116539-58-3/duloxetine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ageing in Marfan syndrome.
Next Document:  Metabolic side effects of antipsychotic medication.